CSL lifts first-half profit
- {{x.value}}
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
We have sent you an email with the details of your registration.
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
- Verify your email address by clicking on the link we sent to {{user.Email}}
- You now have free access, we look forward to helping you on your financial journey.
CSL (CSL) has said its new products are performing well, as it announced a rise in first-half profit.
The medical products supplier posted earnings before interest, tax, depreciation and amortisation of $US912 million in the six months to December 31, up from $US881 million in the previous corresponding half.
The result included a one-off anti-trust litigation settlement in the US totalling $US39 million after tax.
Net profit for the half was $US646 million, up from $US625 million in the first half of 2013.
“The company’s specialty products again performed exceptionally well,” CSL chief executive and managing director Paul Perreault said.
“We’ve also been able to remove the risk and associated distraction with the US anti-trust class action litigation.”
CSL will pay an unfranked interim dividend of US53 cents, or approximately AU59 cents per share, to shareholders on the record at March 12.
Call 1300 880 160
Start a chat
Schedule a call
